BACKGROUND: Dry eye syndrome (DES) has been described by The
International Dry Eye WorkShop as ''multifactorial disease of the tears and
ocular surface that results in symptoms of discomfort, visual disturbance and
tear instability with potential damage to the ocular surface.'' Inflammation
has been recognized as a primary contributor to the disease and was a
tremendous step forward in the description and treatment of DES. Although most
treatments of DES treat inflammation, the signs and symptoms of DES usually
return shortly after discontinuing the use of the anti-inflammatory agent; CASE: We present a case of a 70-year-old patient who presents with
significant dry eye symptoms for 2 years. She reports the need to wear
sunglasses during all waking hours, both indoors and out, and had discontinued
her hobby of gardening. She had ocular rosacea diagnosed at a previous
ophthalmology practice and did not respond to any past treatments. The patient
was treated with 25% platelet-rich plasma (PRP) and experienced significant
improvement and a return to a normal quality of life that has continued for
more than a year after discontinuing treatment; CONCLUSION: Our group is investigating the use of biologic therapeutics
in the treatment of various forms of DES. We suggest that a clinically
acceptable dosage of PRP provides the ocular surface with the components
necessary to restore normal cellular tensegrity and provides a foundation to
eliminate the recurrence of the inflammation associated with DES.
Optometry. 2012 Mar 30;83(3):111-3.
Universityof Missouri-St. Louis College of Optometry, One
University Blvd., St. Louis, MO 63121-4400. Email: email@example.com.